A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

University of Pittsburg Medical Center, Pittsburgh

Fox Chase Cancer Center, Philadelphia

University of Maryland - Greenebaum Cancer Center, Baltimore

Virginia Cancer Specialists, Fairfax

Emory University Winship Cancer Institue, Atlanta

University of Miami - Sylvester Comprehensive Cancer Center, Miami

Tennessee Oncology, Nashville

Vanderbilt Medical Center, Nashville

The West Clinic, Germantown

The Ohio State University, Columbus

Cleveland Clinic, Cleveland

Indiana University Simon Cancer Center, Indianapolis

Barbara Ann Karmanos Cancer Institute, Detroit

Medical College of Wisconsin, Milwaukee

Rush University Medical Center, Chicago

UT Southwestern Medical Center, Dallas

University of Colorado Cancer Center, Aurora

Cedars-Sinai Medical Center, Los Angeles

Swedish Cancer Institute, Seattle

University of Washington, Seattle

Yale School of Medicine, New Haven

Massachusetts General Hospital - Cancer Center, Boston

Beth Israel Deconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Mount Sinai Heath System, New York